Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884452065
Total Employee Number:
61Description
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 174.91 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | 1.29 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8 | |||||
Beneish M-Score | -1.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 84.7 | |||||
3-Year EPS without NRI Growth Rate | 34.7 | |||||
3-Year FCF Growth Rate | 57.4 | |||||
3-Year Book Growth Rate | 7.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 33.41 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.99 | |||||
9-Day RSI | 71.6 | |||||
14-Day RSI | 68.51 | |||||
3-1 Month Momentum % | 9.61 | |||||
6-1 Month Momentum % | 25.12 | |||||
12-1 Month Momentum % | -5.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.89 | |||||
Quick Ratio | 4.84 | |||||
Cash Ratio | 4.27 | |||||
Days Inventory | 38.93 | |||||
Days Sales Outstanding | 25.65 | |||||
Days Payable | 151.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.1 | |||||
Shareholder Yield % | 1.53 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.07 | |||||
Operating Margin % | 8.15 | |||||
Net Margin % | 101.58 | |||||
EBITDA Margin % | 117.67 | |||||
FCF Margin % | 9.81 | |||||
OCF Margin % | 10.44 | |||||
ROE % | 95.28 | |||||
ROA % | 49.2 | |||||
ROIC % | 13.54 | |||||
3-Year ROIIC % | 43.96 | |||||
ROC (Joel Greenblatt) % | 7672.79 | |||||
ROCE % | 64.49 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.25 | |||||
Forward PE Ratio | 14.07 | |||||
Price-to-Owner-Earnings | 6.91 | |||||
PS Ratio | 6.85 | |||||
PB Ratio | 4.15 | |||||
Price-to-Tangible-Book | 4.37 | |||||
Price-to-Free-Cash-Flow | 71.82 | |||||
Price-to-Operating-Cash-Flow | 66.83 | |||||
EV-to-EBIT | 4.63 | |||||
EV-to-EBITDA | 4.54 | |||||
EV-to-Forward-EBITDA | 8.24 | |||||
EV-to-Revenue | 5.35 | |||||
EV-to-Forward-Revenue | 4.62 | |||||
EV-to-FCF | 54.51 | |||||
Price-to-GF-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 5.43 | |||||
| Price-to-Net-Cash | 6.68 | |||||
Earnings Yield (Greenblatt) % | 21.6 | |||||
FCF Yield % | 1.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZVRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zevra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 122.289 | ||
| EPS (TTM) ($) | 1.99 | ||
| Beta | 1.1883 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 1.66 | ||
| Volatility % | 46.62 | ||
| 14-Day RSI | 68.51 | ||
| 14-Day ATR ($) | 0.668327 | ||
| 20-Day SMA ($) | 13.28025 | ||
| 12-1 Month Momentum % | -5.86 | ||
| 52-Week Range ($) | 7.16 - 14.58 | ||
| Shares Outstanding (Mil) | 59.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zevra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zevra Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 35 days | ||
| General meeting for 2026 | 2026-06-04 09:00 | 10.96 (-1.08%) | ||
| H.C. Wainwright BioConnect Investor Conference | 2026-05-19 09:00 | 10.43 (-5.27%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 10.61 (+4.43%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 10.61 (+4.43%) | ||
| Citizens Life Sciences Conference | 2026-03-11 09:00 | 11.06 (+1.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-09 16:30 | 8.98 (+3.10%) |
Show
Entries
Zevra Therapeutics Inc Frequently Asked Questions
What is Zevra Therapeutics Inc(ZVRA)'s stock price today?
The current price of ZVRA is $14.44. The 52 week high of ZVRA is $14.58 and 52 week low is $7.16.
When is next earnings date of Zevra Therapeutics Inc(ZVRA)?
The next earnings date of Zevra Therapeutics Inc(ZVRA) is 2026-08-12 Est..
Does Zevra Therapeutics Inc(ZVRA) pay dividends? If so, how much?
Zevra Therapeutics Inc(ZVRA) does not pay dividend.
Guru Commentaries on NAS:ZVRA
No articles.
Press Release
Articles on Zevra Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers